A02 Probing the roles of SUMOylation in B-cell lymphoma cells by using a selective SUMO inhibitor Subasumstat (TAK-981). Tingting Liu. City of Hope, Duarte, CA, United States.

A03 Discovery and evaluation of GT19630, a c-Myc/n-Myc degrader, for targeting c-Myc-driven B-cell malignancies, acute myeloid leukemia (AML) and n-Myc driven cancers. Liandong Ma. Kintor Pharmaceutical Limited, Suzhou, China (Mainland).

A04 Targeted protein degradation as a strategy to overcome non-covalent BTK inhibitor resistance in lymphoma. Skye Montoya. Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL, United States.

A05 Olfactory receptors as a new therapeutic target in lymphomas. Giulio Sartori. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.


A07 BTM 3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in vitro and in vivo in Diffuse Large B-cell Lymphoma. Matthew Kostura. Bantam Pharmaceutical, Research Triangle Park, NC, United States.

A08 Diagnosis of breast implant associated anaplastic large cell lymphoma by analysis of cytokines in peri-implant effusions. Marshall E. Kadin. Brown Alpert School of Medicine, Providence, RI, United States.

A09 Telomerase activity as a biomarker to predict outcomes of CAR T-cell therapy. Praveen Ramakrishnan Geethakumari. UT Southwestern Medical Center, Dallas, TX, United States.

A10 Radio labelled AMD3100 for the management of malignant lymphoma: Translational study. Jaya Shukla. Post Graduate Institute of Medical Education and Research, Chandigarh, India.

A11 The International Prognostic Score and HIV status predict red cell concentrate transfusion need in Hodgkin Lymphoma. Estelle R Verburgh. University of Cape Town, Cape Town, South Africa.


A13 Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Erin M Parry. Dana-Farber Cancer Institute, Boston, MA, United States.

A14 The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle and RNA processing. Giulio Sartori. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
A15 Clinico-pathologic and molecular characteristics of primary extranodal germinal-center B-cell like diffuse large B-cell lymphoma (EN GCB-DLBCL). Brian Lue. UT Southwestern Medical Center, Dallas, TX, United States.

A16 Liquid biopsy for the detection and characterization of canine lymphoma. Angela L. McCleary-Wheeler. PetDx, La Jolla, CA, United States.

A17 The immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Jay Gunawardana. Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.

A18 GRK2, an inhibitor of MALT1-dependent oncogenic signaling, is downregulated by microRNA in ABC-DLBCL. Jing Cheng. University of Pittsburgh, Pittsburgh, PA, United States.


A21 Novel autochthonous mouse models as preclinical tools in the study of MCD/C5 DLBCL. Gero Knittel. Essen University Hospital, Essen, Germany.


A23 Alternative cyclin D1 transcripts in Mantle Cell Lymphoma. Chioniso P. Masamha. Butler University, Indianapolis, IN, United States.

A24 BTG1 mutations confer a fitness advantage and promote aggressive B cell lymphoma development by lowering the threshold for MYC induction. Coraline Mlynarczyk. Weill Cornell Medicine, New York City, NY, United States.


A26 SOX11 drives B1a lineage commitment and B1a/MCL-like lymphoma formation in mice. Tim Pieters. Ghent University, Ghent, Belgium.

A28 BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL. Min Xia. Weill Cornell Medicine, New York, NY, United States.


A32 Copanlisib plus rituximab vs placebo plus rituximab in patients with follicular lymphoma: 1-year follow-up of the Phase III, randomized CHRONOS-3 trial. Marcelo Capra. Centro de Hematología e Oncología, Hospital Mãe de Deus, Porto Alegre, Brazil.

A36 Building of a large B-cell lymphoma (LBCL) patient-derived xenograft (PDX) repository. Haopeng Yang. University of Texas MD Anderson Cancer Center, Houston, TX, United States.


A38 Cd70 genetic perturbation limits the development of an effective CD8 + T-cell immune response to Bcl6-driven diffuse large B-cell lymphoma. Elisa Mandato. Dana-Farber Cancer Institute, Boston, MA, United States.

A39 Targeting tumor-microenvironmental dependencies as a therapeutic approach in Chronic Lymphocytic Leukemia (CLL). Salma Parvin. Dana Farber Cancer Institute, Boston, MA, United States.

A40 Evaluation of the tumor microenvironment in Mycosis Fungoides using the PanCancer IO 360 TM assay and nCounter® platform. Jesse Jaso. The University of Texas Southwestern Medical Center, Dallas, TX, United States.